Effects of a β-blocker on bone turnover in normal postmenopausal women: A randomized controlled trial

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 9, 2005, Pages 5212-5216

  Reid, Ian R ^a   Lucas, Jenny ^a   Wattie, Diana ^a   Horne, Anne ^a   Bolland, Mark ^a   Gamble, Gregory D ^a   Davidson, James S ^b   Grey, Andrew B ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBOXY TERMINAL TELOPEPTIDE; CELL MARKER; CREATININE; OSTEOCALCIN; PLACEBO; PROCOLLAGEN; PROPRANOLOL; SERUM ALBUMIN;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; ENZYME ACTIVITY; FEMALE; FLUID BALANCE; HUMAN; KIDNEY FUNCTION; LUMBAR SPINE; OSSIFICATION; OSTEOBLAST; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME SERIES ANALYSIS;

ADRENERGIC BETA-ANTAGONISTS; AGED; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; FEMALE; FEMUR; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; POSTMENOPAUSE; PROPRANOLOL; REFERENCE VALUES;

EID: 24344491882     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2005-0573     Document Type: Article

References (41)

1. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen JH, Vinson C, Rueger JM, Karsenty G 2000 Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100:197-207
2. Baldock PA, Sainsbury A, Couzens M, Enriquez RF, Thomas GP, Gardiner EM, Herzog H 2002 Hypothalamic Y2 receptors regulate bone formation. J Clin Invest 109:915-921
3. Takeda S, Elefteriou F, Levasseur R, Liu XY, Zhao LP, Parker KL, Armstrong D, Ducy P, Karsenty G 2002 Leptin regulates bone formation via the sympathetic nervous system. Cell 111:305-317
4. Pasco JA, Henry MJ, Sanders KM, Kotowicz MA, Seeman E, Nicholson GC 2004 β-Adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J Bone Miner Res 19:19-24
5. Schlienger RG, Kraenzlin ME, Jick SS, Meier CR 2004 Use of β-blockers and risk of fractures. JAMA 292:1326-1332
6. Rejnmark L, Vestergaard P, Kassem M, Christoffersen BR, Kolthoff N, Brixen K, Mosekilde L 2004 Fracture risk in perimenopausal women treated with β-blockers. Calcif Tissue Int, 75:365-372
7. Reid IR, Gamble GD, Grey AB, Black DM, Ensrud KE, Browner WS, Bauer DC 2005 β-Blocker use, BMD, and fractures in the study of osteoporotic fractures. J Bone Miner Res 20:613-618
8. Levasseur R, Marcelli C, Sabatier JP, Dargent-Molina P, Breart G 2005 β-Blocker use, bone mineral density, and fracture risk in older women: results from the Epidemiologie de l'Osteoporose prospective study. J Am Geriatr Soc 53:550-552
9. Morrison NA, Shine J, Fragonas JC, Verkest V, McMenemy ML, Eisman JA 1989 1,25-Dihydroxyvitamin D-responsive element and glucocorticoid repression in the osteocalcin gene. Science 246:1158-1161
10. 2+ movement and cytotoxicity in human MG63 osteosarcoma cells. Basic Clin Pharmacol Toxicol 95:59-65
11. Apone S, Lee MY, Eyre DR 1997 Osteoclasts generate cross-linked collagen N-telopeptides (NTx) but not free pyridinolines when cultured on human bone. Bone 21:129-136
12. Wilkinson R, Stevens IM, Pickering M, Robson V, Hawkins T, Kerr DN, Harry JD 1980 A study of the effects of atenolol and propranolol on renal function in patients with essential hypertension. Br J Clin Pharmacol 10:51-59
13. Ibsen H, Sederberg-Olsen P 1973 Changes in glomerular filtration rate during long-term treatment with propranolol in patients with arterial hypertension. Clin Sci 44:129-134
14. Okabe R, Nakatsuka K, Inaba M, Miki T, Naka H, Masaki H, Moriguchi A, Nishizawa Y 2001 Clinical evaluation of the Elecsys β-CrossLaps serum assay, a new assay for degradation products of type I collagen C-telopeptides. Clin Chem 47:1410-1414
15. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer J, Kaufman J, Jaeger P, Body J, Meunier PJ 2002 Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653-661
16. Sederberg-Olsen P, Ibsen H 1972 Plasma volume and extracellular fluid volume during long-term treatment with propranolol in essential hypertension. Clin Sci 43:165-170
17. Hvarfner A, Bergstrom R, Lithell H, Morlin C, Wide L, Ljunghall S 1988 Changes in calcium metabolic indices during long-term treatment of patients with essential hypertension. Clin Sci (Lond) 75:543-549
18. Kukreja SC, Williams GA, Vora NM, Hargis GK 1981 Normal responsiveness of serum parathyroid hormone to β-adrenergic blockade in patients with secondary hyperparathyroidism. Horm Metab Res 13:233-235
19. Joborn H, Bergstrom R, Rastad J, Wide L, Akerstrom G, Ljunghall S 1988 Effects of propranolol and verapamil on plasma ionized calcium and parathyroid hormone in short-term intense isokinetic leg exercise. Clin Physiol 8:1-7
20. Perrild H, Jessen-Jurgensen H, Pedersen F, Fogh-Andersen N 1988 Serum magnesium, calcium, phosphate and PTH following long-term β-blockade in ischaemic heart disease. Eur J Clin Pharmacol 34:299-301
21. Imai Y, Rodan SB, Rodan GA 1988 Effects of retinoic acid on alkaline phosphatase messenger ribonucleic acid, catecholamine receptors, and G proteins in ROS 17/2.8 cells. Endocrinology 122:456-463
22. Rodan SB, Rodan GA 1986 Dexamethasone effects on β-adrenergic receptors and adenylate cyclase regulatory proteins Gs and Gi in ROS 17/2.8 cells. Endocrinology 118:2510-2518
23. Moore RE, Smith 2nd CK, Bailey CS, Voelkel EF, Tashjian Jr AH 1993 Characterization of β-adrenergic receptors on rat and human osteoblast-like cells and demonstration that β-receptor agonists can stimulate bone resorption in organ culture. Bone Miner 23:301-315
24. Kellenberger S, Muller K, Richener H, Bilbe G 1998 Formoterol and isoproterenol induce c-fos gene expression in osteoblast-like cells by activating β2-adrenergic receptors. Bone 22:471-478
25. Kondo A, Mogi M, Koshihara Y, Togari A 2001 Signal transduction system for interleukin-6 and interleukin-11 synthesis stimulated by epinephrine in human osteoblasts and human osteogenic sarcoma cells. Biochem Pharmacol 61:319-326
26. Takeuchi T, Tsuboi T, Arai M, Togari A 2001 Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. Biochem Pharmacol 61:579-586
27. Kondo A, Togari A 2003 In vivo stimulation of sympathetic nervous system modulates osteoblastic activity in mouse calvaria.AmJ Physiol 285:E661-E667
28. Schmitt CP, Obry J, Feneberg R, Veldhuis JD, Mehls O, Ritz E, Schaefer F 2003 β1-Adrenergic blockade augments pulsatile PTH secretion in humans. J Am Soc Nephrol 14:3245-3250
29. Dietrich JW, Mundy GR, Raisz LG 1979 Inhibition of bone resorption in tissue culture by membrane-stabilizing drugs. Endocrinology 104:1644-1648
30. Pierroz DD, Bouxsein ML, Glatt V, Rizzoli R, Ferrari SL 2004 Intermittent PTH and propranolol have synergistic effects on vertebral trabecular bone in ovariectomized mice. J Bone Miner Res 19:S460
31. Minkowitz B, Boskey AL, Lane JM, Pearlman HS, Vigorita VJ 1991 Effects of propranolol on bone metabolism in the rat. J Orthopaed Res 9:869-875
32. Levasseur R, Sabatier JP, Potrel-Burgot C, Lecoq B, Creveuil C, Marcelli C 2003 Sympathetic nervous system as transmitter of mechanical loading in bone. Joint Bone Spine 70:515-519
33. Suzuki A, Palmer G, Bonjour JP, Caverzasio J 1998 Catecholamines stimulate the proliferation and alkaline phosphatase activity of MC3T3-E1 osteoblast-like cells. Bone 23:197-203
34. Zeman RJ, Hirschman A, Hirschman ML, Guo G, Etlinger JD 1991 Clenbuterol, a β2-receptor agonist, reduces net bone loss in denervated hindlimbs. Am J Physiol 261:E285-E289
35. Pataki A, Muller K, Bilbe G, Green JR, Glatt M 1996 Anabolic effects of β2-agonists, formoterol and salbutamol on cancellous bone of ovariectomized rat. Bone 9:A116
36. Cherruau M, Facchinetti P, Baroukh B, Saffar JL 1999 Chemical sympathectomy impairs bone resorption in rats: a role for the sympathetic system on bone metabolism. Bone 25:545-551
37. Hill EL, Turner R, Elde R 1991 Effects of neonatal sympathectomy and capsaicin treatment on bone remodeling in rats. Neuroscience 44:747-755
38. Sandhu HS, Herskovits MS, Singh IJ 1987 Effect of surgical sympathectomy on bone remodeling at rat incisor and molar root sockets. Anat Rec 219:32-38
39. Ke HZ, Xu G, Brault AL, Qi H, Crawford DT, Simmons HA, Li M, Brown TA 2004 Deletion of the β2 adrenergic receptor prevents bone loss induced by isoproterenol in mice. J Bone Miner Res 19:S3
40. Pierroz DD, Muzzin P, Glatt V, Bouxsein ML, Rizzoli R, Ferrari SL 2004 β1β2-Adrenergic receptor KO mice have decreased total body and cortical bone mass despite increased trabecular number. J Bone Miner Res 19:S32
41. Dhillon H, Glatt V, Ferrari SL, Bouxsein ML 2004 β-Adrenergic receptor KO mice have increased bone mass and strength but are not protected from ovariectomy-induced bone loss. J Bone Miner Res 19:S32